|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400088539 |
|
最近更新日期: Date of Last Refreshed on: |
2024-08-21 08:52:50 |
|
注册时间: Date of Registration: |
2024-08-21 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中亚地区肾脏替代治疗患者现状调查分析:一项回顾性多中心横断面研究 |
|
Public title: |
A retrospective multicenter cross-sectional study on the current status of renal replacement therapy patients in Central Asia |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中亚地区肾脏替代治疗患者现状调查分析:一项回顾性多中心横断面研究 |
|
Scientific title: |
A retrospective multicenter cross-sectional study on the current status of renal replacement therapy patients in Central Asia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王顺 |
研究负责人: |
陆晨 |
|
Applicant: |
wangshun |
Study leader: |
luchen |
|
申请注册联系人电话: Applicant telephone: |
+86 139 9929 0323 |
研究负责人电话:
Study leader's |
+86 138 9998 7276 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wangshun128@126.com |
研究负责人电子邮件: Study leader's E-mail: |
luchen706@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
新疆医科大学第一附属医院 |
研究负责人通讯地址: |
新疆医科大学第一附属医院 |
|
Applicant address: |
The First Affiliated Hospital of Xinjiang Medical University |
Study leader's address: |
The First Affiliated Hospital of Xinjiang Medical University |
|
申请注册联系人邮政编码: Applicant postcode: |
830000 |
研究负责人邮政编码: Study leader's postcode: |
830000 |
|
申请人所在单位: |
新疆医科大学第一附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Xinjiang Medical University |
||
|
研究负责人所在单位: |
新疆医科大学第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Xinjiang Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
K202406-16 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
新疆医科大学第一附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-06-27 00:00:00 | ||
|
伦理委员会联系人: |
刘剑 |
||
|
Contact Name of the ethic committee: |
Liu Jian |
||
|
伦理委员会联系地址: |
新疆医科大学第一附属医院 |
||
|
Contact Address of the ethic committee: |
The First Affiliated Hospital of Xinjiang Medical University |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 139 9929 0323 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
wangshun128@126.com |
|
研究实施负责(组长)单位: |
新疆医科大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Xinjiang Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
新疆维吾尔自治区乌鲁木齐市鲤鱼山南路137号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 137, Liyushan South Road, Urumqi City, Xinjiang Uygur Autonomous Region |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
raise independently |
||||||||||||||||||||||
|
研究疾病: |
慢性肾脏病 |
||||||||||||||||||||||
|
Target disease: |
Chronic kidney disease |
||||||||||||||||||||||
|
研究疾病代码: |
N18.0 |
||||||||||||||||||||||
|
Target disease code: |
N18.0 |
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
本团队计划在中亚地区现场/远程开展维持性血液透析患者的治疗过程及其生活质量的评估,以期降低致死(残)率、诊疗费用、并发症、合并症、提升满意度。 |
||||||||||||||||||||||
|
Objectives of Study: |
Our team plans to conduct on-site/remote evaluations of the treatment process and quality of life for maintenance hemodialysis patients in Central Asia, in order to reduce mortality (disability) rates, diagnosis and treatment costs, complications, comorbidities, and improve satisfaction. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
① 正在接受血液透析的患者; ② 同意调查研究并自愿签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
① Patients undergoing hemodialysis; ② Agree to investigate and voluntarily sign an informed consent form. |
||||||||||||||||||||||
|
排除标准: |
不愿配合调查研究者或其他原因不能配合调查者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Not willing to cooperate with the investigator or unable to cooperate with the investigator for other reasons. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-10-01 00:00:00至 To 2025-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-10-01 00:00:00 至 To 2025-07-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由第三方统计人员运用SPSS统计软件,采用随机数字表法生成随机方案 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Generate a random plan using the random number table method using SPSS statistical software by third-party statisticians |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
临床试验公共管理平台http://www.medresman.org.cn/login.aspx,在试验结束6个月内上传试验数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Clinical Trial Public Management Platform http://www.medresman.org.cn/login.aspx Upload test data within 6 months after the end of the experiment |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |